Halia bets on genetic resilience against Alzheimer’s

New data links Halia’s Alzheimer’s program to a prevention trial targeting people at high genetic risk before symptoms appear. Alzheimer’s drug development has long focused on treating the disease once memory problems have already appeared. Halia Therapeutics believes that may simply be too late. At the Alzheimer’s Association International Conference (AAIC) 2026, the Utah-based biotech […] The post Halia bets on genetic resilience against Alzheimer’s appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.